



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## Prone positioning might reduce the need for intubation in people with severe COVID-19

### Authors' reply

We thank W Cameron McGuire and colleagues for their comments regarding our meta-trial on awake prone positioning in patients with COVID-19.<sup>1</sup> We would like to clarify some points.

First, concerning the fragility index, superiority randomised controlled trials are carefully designed to recruit the fewest patients necessary to detect a clinically meaningful and statistically significant difference. This is the objective of sample size calculations and interim analyses. This leads, by design, to low fragility index values. There is no specific cutoff value to classify a study as fragile or robust. Randomised trials that changed clinical practice, published in high-impact journals have a median fragility index of 5,<sup>2</sup> and the median fragility index in critical care randomised trials is 3.<sup>3</sup> Although fragility index is an increasingly popular metric to allegedly show the robustness of trial results, it has also been referred to as a p value in disguise and a potentially misleading metric.<sup>4</sup> In the hypothetical case regarding patients who withdrew consent, McGuire and colleagues could have calculated that 226 events in 567 patients in the awake prone positioning group and 257 events in 559 patients in the control group yields a p value of 0.041 with a Fisher's exact test. We must stress that the robustness of a study relies on its design, study implementation, analysis plan, effect sizes, CIs, generalisability, and limitations, and not on a single integer derived from an inappropriate secondary analysis of a hypothetical randomised trial that never occurred.<sup>2</sup>

Second, all patients in Mexico were recruited in a COVID-19-dedicated intensive care unit and two intermediate care units, which differed

only by nurse-to-patient ratios (1:2 and 1:4, respectively). All patients were provided high-level care by experienced critical care physicians, and no intubations were delayed because of unavailability of ventilators or staff.

Third, McGuire and colleagues note a lower baseline SpO<sub>2</sub>:FiO<sub>2</sub> ratio in the Mexican trial and worry that a lower threshold for intubation described in the Mexican protocol could have led to a lower intubation rate. These moderate variations in care and population between trials do not create any bias in the estimation of the intervention effect, as the randomisation was stratified on the trial. Indeed, it is clear from our appendix<sup>1</sup> that intubation rates were not different among the three large trials (158 [39%] of 402 patients in France, 77 [34%] of 222 patients in the USA, and 157 [36%] of 430 patients in Mexico). The decision to intubate is complex, comprising clinical judgement, and gestalt and tacit knowledge that have evolved even during the pandemic,<sup>5</sup> and cannot be decided by a single oxygenation parameter. Slight differences between protocols should not distract us from the pragmatic and robust finding of reduced intubation rates with awake prone positioning.

Taken together, the results of our meta-trial are at least as robust as most carefully designed randomised trials and are valid and practice changing.

SE discloses consultancies from Aerogen Ltd, research support from Aerogen Ltd, Fisher & Paykel Healthcare Ltd, Hamilton medical, travel reimbursements from Aerogen Ltd and Fisher & Paykel Healthcare Ltd. JL discloses research funding from Fisher & Paykel Healthcare Ltd, Aerogen Ltd, and Rice Foundation, and speaker fees from AARC, Aerogen Ltd, Heyer, and Fisher & Paykel Healthcare Ltd. IP discloses a research grant and speaker fees from Fisher & Paykel Healthcare Ltd. YP discloses research support from Fisher & Paykel Healthcare Ltd. OR discloses a research grant from Hamilton Medical and speaker fees from Hamilton Medical, Ambu and Aerogen Ltd, and non-financial research support from Timpel and Masimo Corporation. OR's institution received fees for consultancy from Hamilton Medical. DV discloses research funding from Teleflex Medical, Inc and Rice Foundation, and speaker fees from Theravance Biopharma.

JGL discloses consulting fees from Baxter Healthcare and Glaxosmithkline. All other authors have no competing interests to disclose.

Miguel Ibarra-Estrada, \*Jie Li,  
John G Laffey, Ivan Pavlov, Oriol Roca,  
Yonatan Perez, Bairbre McNicholas,  
David Vines, Elsa Tavernier,  
Stephan Ehrmann  
jie\_li@rush.edu

Unidad de Terapia Intensiva, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico (MI-E); Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, Chicago, IL 60612, USA (JL, DV); Department of Anesthesia and Intensive Care Medicine, Galway University Hospitals, HRB Galway Clinical Research Facility, and School of Medicine, National University of Ireland, Galway, Ireland (JGL, BM); Department of Emergency Medicine, Hôpital de Verdun, Montreal, QC, Canada (IP); Servei de Medicina Intensiva, Hospital Universitari Vall d'Hebron, Barcelona, Spain (OR); Ciber Enfermedades Respiratorias (CibeRes), Instituto de Salud Carlos III, Madrid, Spain (OR); CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSep FCRIN research network, Tours, France (YP, SE); INSERM, Centre d'étude des pathologies respiratoires, U1100, Université de Tours, Tours, France (YP, SE); Clinical Investigation Center, INSERM 1415, CHRU Tours, Tours, France and Methods in Patients-Centered Outcomes and Health Research, INSERM UMR 1246, Nantes, France (ET)

- Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. *Lancet Respir Med* 2021; **9**: 1387-95.
- Niforatos JD, Zheutlin AR, Chaitoff A, Pescatore RM. The fragility index of practice changing clinical trials is low and highly correlated with p-values. *J Clin Epidemiol* 2020; **119**: 140-42.
- Grolleau F, Collins GS, Smarandache A, et al. The fragility and reliability of conclusions of anesthesia and critical care randomized trials with statistically significant findings: a systematic review. *Crit Care Med* 2019; **47**: 456-62.
- Ho AK. The fragility index for assessing the robustness of the statistically significant results of experimental clinical studies. *J Gen Intern Med* 2021; published online Aug 6. <https://doi.org/10.1007/s11606-021-06999-9>.
- Tobin MJ. The criteria used to justify endotracheal intubation of patients with COVID-19 are worrisome. *Can J Anaesth* 2021; **68**: 258-59.



If you would like to respond to an article published in *The Lancet Respiratory Medicine*, please submit your correspondence online at: <http://ees.elsevier.com/thelancetrm>